Bristol-Myers Squibb Company

BMY

US1101221083

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

Pharmaceuticals

Calendar

07:30pm - Annual General Meeting

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 11:36 pm IST

More Strategies

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

43.9 USD

Average target price

53.19 USD

Spread / Average Target

+21.17%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BRISTOL-MYERS SQUIBB COMPANY	-14.09%	88.99B
ELI LILLY AND COMPANY	+32.95%	690B
NOVO NORDISK A/S	+26.43%	546B
JOHNSON & JOHNSON	-4.89%	358B
MERCK & CO., INC.	+18.17%	323B
ABBVIE INC.	+4.87%	287B
ASTRAZENECA PLC	+14.32%	235B
NOVARTIS AG	+5.79%	199B
ROCHE HOLDING AG	-9.49%	195B
AMGEN INC.	+4.76%	161B

Other Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 09:45:05 07/05/2024 pm IST			5-day change	1st Jan Change
44.14 ^USD	+0.54%		+0.32%	-14.09%

06/05	Top Midday Stories: Tyson Shares Tumble on Earnings Miss; Robinhood Receives Wells Notice From SEC Staff; Spirit Airlines to Furlough up to 260 Pilots; Shell in Talks to Sell Malaysian Gas Station Business to Saudi Aramco	MT
06/05	Bristol-Myers Squibb Says Applications for Opdivo Accepted by US, European Regulators	MT

Top Midday Stories: Tyson Shares Tumble on Earnings Miss; Robinhood Receives Wells Notice From SEC Staff; Spirit Airlines to Furlough up to 260 Pilots; Shell in Talks to Sell Malaysian Gas Station Business to Saudi Aramco	06/05	MT
Bristol-Myers Squibb Says Applications for Opdivo Accepted by US, European Regulators	06/05	MT
Bristol-Myers Gets FDA Acceptance of Review for Subcutaneous Opdivo Formulation	06/05	DJ
Bristol-Myers: BLA accepted for subcutaneous Opdivo	06/05	CF
U.S. Food and Drug Administration Accepts Bristol Myers Squibb?s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)	06/05	CI
European Medicines Agency Validates Bristol Myers Squibb?s Application for Opdivo Plus Yervoy for the First-Line Treatment of Adult Patients with Microsatellite Instability?High or Mismatch Repair Deficient Metastatic Colorectal Cancer	06/05	CI
HSBC Adjusts Price Target on Bristol-Myers Squibb to $45 From $50	01/05	MT
Editas Medicine, Bristol-Myers Squibb Extend Alpha-Beta T Cell Collaboration	01/05	MT
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration	01/05	CI
Global markets live: Adidas, Mercedes, McDonalds, Eli Lilly, PayPal, MicroStrategy, Tesla...	30/04
A flurry of corporate results ahead of the Fed's rate decision	30/04
ANALYST RECOMMENDATIONS : Tesla, Snap, Alphabet, Microsoft, Anglo American...	30/04
Scenic Biotech Enters into Research Collaboration with Bristol Myers Squibb	30/04	CI
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion	30/04	RE
J&J, Bristol Myers lose challenges to US drug price negotiation program	30/04	RE
Goldman Sachs Cuts Bristol-Myers Squibb's Price Target to $56 From $60	29/04	MT
Deutsche Bank Adjusts Price Target on Bristol-Myers Squibb to $53 From $55, Keeps Hold Rating	29/04	MT
Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases	29/04	CI
S&P 500 Q1 earnings estimated growth improves; stocks up for week	27/04	RE
Leerink Partners Cuts Price Target on Bristol-Myers Squibb to $47 From $51	26/04	MT
UBS Cuts Bristol-Myers Squibb Price Target to $47 From $52, Maintains Neutral Rating	26/04	MT
Barclays Adjusts Price Target on Bristol-Myers Squibb to $43 From $51	26/04	MT
JPMorgan Adjusts Bristol-Myers Squibb's Price Target to $60 From $65	26/04	MT
Bristol-Myers Squibb Says European Regulator Recommends Approval of Bladder Cancer Combination Therapy	26/04	MT
Bristol Myers: positive opinion from the CHMP for Opdivo	26/04	CF